Dirk Huebner Net Worth

Dirk Huebner biography

Dr. Dirk Huebner M.D. serves as Chief Medical Officer of the Company. Previously, from August 2017 to November 2018, Dr. Huebner served as Vice President, Head of Development, for Boston Biomedical. Prior to that, he spent six years at Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda focused on oncology, as Executive Medical Director. Prior to that, he held roles of increasing leadership and responsibility in global clinical drug development at Genzyme, Roche, and Bristol-Myers Squibb..

What is the salary of Dirk Huebner?

As the Chief Medical Officer of Mersana Therapeutics Inc, the total compensation of Dirk Huebner at Mersana Therapeutics Inc is 1,147,800$. There are 1 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of 1,739,800$.

How old is Dirk Huebner?

Dirk Huebner is 57, he's been the Chief Medical Officer of Mersana Therapeutics Inc since 2018. There are 5 older and 12 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.

What's Dirk Huebner's mailing address?

Dirk's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Mersana Therapeutics Inc

Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over 1,068,087$ worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth 226,822,416$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of 534,621$. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth 153,916$.

What does Mersana Therapeutics Inc do?

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Mersana Therapeutics Inc executives and stock owners

Mersana Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anna Protopapas,
  President, Chief Executive Officer, Director
• Dirk Huebner,
  Chief Medical Officer
• Timothy Lowinger,
  Chief Science and Technology Officer
• Brian DeSchuytner,
  Senior Vice President - Finance and Product Strategy
• Anna Protopapas,
  Pres, CEO & Director
• Anna Protopapas M.B.A.,
  Pres, CEO & Director
• Dr. Timothy B. Lowinger,
  Chief Science & Technology Officer
• Brian C. DeSchuytner,
  Sr. VP & CFO
• Dr. Arvin Yang M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Alejandra Veronica Carvajal J.D.,
  SVP, Sec. & Chief Legal Officer
• Dr. Tushar Misra Ph.D.,
  SVP & Chief Manufacturing Officer
• David Mott,
  Independent Chairman of the Board
• Lawrence Alleva,
  Independent Director
• Willard Dere,
  Independent Director
• Andrew Hack,
  Independent Director
• Kristen Hege,
  Independent Director
• Martin Huber,
  Independent Director
• Eva Jack,
  Chief Business Officer
• Chuck Miller,
  Senior Vice President - Regulatory Affairs
• Michael Kaufman,
  Senior Vice President - Chemistry, Manufacturing and Controls
• Alejandra Veronica Carvajal,
  Sr. VP & Chief Legal Officer
• Carla Poulson,
  Chief HR Officer
• Radha Iyengar,
  VP of Legal Operations
• Sarah Carmody,
  Exec. Director of Investor Relations & Corp. Communications
• Ashish Mandelia,
  VP, Controller & Principal Accounting Officer
• Mikhail Papisov Ph.D.,
  Co-Founder
• Llc Fmr,
  
• Peter J Barris,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Ravi Viswanathan,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Patrick J Kerins,
  10% owner
• Scott D Sandell,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Sara M. Nayeem,
  Director
• Wayne Foster,
  Vice President of Finance
• Donald A Bergstrom,
  Chief Medical Officer
• David A Spellman,
  Chief Financial Officer
• Enterprise Associates 14, L...,
  
• Partners 14, L.P.Nea 14 Gp,...,
  
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  10% owner
• Allene M. Diaz,
  Director
• Mohan Bala,
  SVP, Chief Development Officer
• Arvin Yang,
  SVP, Chief Medical Officer
• Ashish Mandelia,
  VP, Chief Accounting Officer
• Tushar Misra,
  SVP, Chief Manuf. Officer